By Barbara Obstoj-Cardwell. Editor
Regulatory news last week featured the combination of Padcev and Keytruda, developed by US biotech Seagen and Japan’s Astellas Pharma, gaining accelerated approval from the US Food and Drug Administration (FDA) for the treatment of urothelial cancer. Also, Germany’s InflaRx gained emergency use authorization (EUA) for its COVID-19 treatment Gohibic (vilobelimab). On the research front, US biotech OncoSec Medical had a major setback last week, when it reported that its TAVO-EP, in combination with Merck & Co’s mega-blockbuster immune-oncology drug Keytruda, missed the endpoint of a Phase II study in melanoma. With better news, UK pharma major AstraZeneca announced positive results from the DUO-O Phase III trial of Lynparza in combination with Imfinzi for the treatment of ovarian cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze